Cannabinoid Receptor Antagonists
"Cannabinoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.
| Descriptor ID |
D063387
|
| MeSH Number(s) |
D27.505.519.625.085.750 D27.505.696.399.472.188.750
|
| Concept/Terms |
Cannabinoid Receptor Antagonists- Cannabinoid Receptor Antagonists
- Antagonists, Cannabinoid Receptor
- Receptor Antagonists, Cannabinoid
- Cannabinoid Receptor Blockers
- Blockers, Cannabinoid Receptor
- Receptor Blockers, Cannabinoid
- Cannabinoid Antagonists
- Antagonists, Cannabinoid
- Cannabinoid Blockers
- Blockers, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Cannabinoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Cannabinoid Receptor Antagonists".
This graph shows the total number of publications written about "Cannabinoid Receptor Antagonists" by people in this website by year, and whether "Cannabinoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cannabinoid Receptor Antagonists" by people in Profiles.
-
Ippolito M, Hayduk SA, Kinney W, Brenneman DE, Ward SJ. KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats. J Pharmacol Exp Ther. 2024 10 18; 391(2):231-240.
-
Myers AM, Siegele PB, Foss JD, Tuma RF, Ward SJ. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br J Pharmacol. 2019 05; 176(10):1552-1567.
-
Reichenbach ZW, Li H, Ward SJ, Tuma RF. The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia. Neurosci Lett. 2016 Sep 06; 630:9-15.
-
Amenta PS, Jallo JI, Tuma RF, Hooper DC, Elliott MB. Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J Neuroinflammation. 2014 Nov 22; 11:191.
-
Bergamaschi MM, Queiroz RH, Chagas MH, Linares IM, Arrais KC, de Oliveira DC, Queiroz ME, Nardi AE, Huestis MA, Hallak JE, Zuardi AW, Moreira FA, Crippa JA. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol. 2014 Jan; 29(1):94-9.
-
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.
-
Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res. 2012 Feb; 134(2-3):207-10.